The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...
The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...
Vraylar may lead to mild side effects such as movement issues, restlessness, sleepiness, and weight gain, which are often temporary. Serious side effects may occur, including neuroleptic malignant ...
Reddit threads provide anecdotal information, which can be validating and comforting. But Vraylar’s prescribing information provides the clinical data. This article explores the most common questions ...
AbbVie ABBV announced that the FDA has approved Vraylar (cariprazine) for the adjunctive treatment of patients with major depressive disorder (MDD). Vraylar is presently approved for treating ...
NEW ORLEANS -- Adjunctive cariprazine (Vraylar) was linked with a reduction in depressive symptoms for patients with major depressive disorder (MDD), who had an inadequate response to current therapy, ...
The FDA has approved the use of Vraylar (cariprazine; Allergan) to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults. The Food and Drug Administration (FDA) ...
On Dec. 16, the U.S. Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Vraylar the go-ahead as an adjunctive (add-on) treatment for patients with major depressive disorder (MDD). What was ...
AbbVie’s antipsychotic Vraylar could get a major boost from a potential expansion into depression. But like some other late-stage contenders, the drug’s clinical results fell short of a home run.
The sNDA included findings from the RGH-MD-53, RGH-MD-54, and RGH-MD-56 trials in which cariprazine was associated with greater improvement in change from baseline to week 6 on the Montgomery Asberg ...
Allergan plc, a leading global pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results